ConductScience.org, home

Comparison · NCT01706198-00ef6e22

FF/VI vs Usual Care: Number of Participants With Fatal SAEs of Pneumonia

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. FF/VI vs Usual Care: Number of Participants With Fatal SAEs of Pneumonia. Trial comparisons, record NCT01706198-00ef6e22. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01706198-00ef6e22

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.0004730.00008350.00267wilson
Risk in group 20.001420.0004820.00415wilson
Risk difference, group 1 minus group 2-0.000943-0.003710.00145newcombe hybrid score
Risk ratio, group 1 over group 20.3340.03483.21log
Odds ratio, group 1 over group 20.3340.03473.21log
Number needed to treat, for one fewer participant with the outcome on FF/VI than on Usual Care1,060from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1FF/VIParticipants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler.12,114OG001
Group 2Usual Care
Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers).
32,119OG000

Outcome

Type
SECONDARY
Title
Number of Participants With Fatal SAEs of Pneumonia
Description
All SAEs included in the AESI group of pneumonia were considered as an SAE of pneumonia. Fatal SAEs of pneumonia are SAEs that led to death of participants. The number of participants with fatal SAEs of pneumonia has been presented.
Time frame
Up to Week 52
Population
ITT Population

Source ClinicalTrials.gov

Trial

Title
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
NCT number
NCT01706198
Phases
PHASE3
Conditions
Asthma
Interventions
fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
Lead sponsor
GlaxoSmithKline
Results first posted
2019-01-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01706198-00ef6e22